Methods for Treating HCV

Abstract

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

What is claimed is: 
     
         1 . A method of treatment for HCV genotype 1, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to a patient infected with HCV genotype 1, wherein said treatment lasts for 4 or 6 weeks and does not include administration of interferon to said patient, wherein said at least two DAAs comprise 
       
         
           
           
               
               
           
         
       
       and another DAA, and wherein Compound 1 is administered with ritonavir. 
     
     
         2 . The method of  claim 1 , wherein said treatment lasts for 4 weeks. 
     
     
         3 . The method of  claim 1 , wherein said treatment lasts for 6 weeks. 
     
     
         4 . The method of  claim 1 , wherein said patient is a treatment-naïve patient. 
     
     
         5 . The method of  claim 2 , wherein said patient is a treatment-naïve patient. 
     
     
         6 . The method of  claim 3 , wherein said patient is a treatment-naïve patient.